OTCMKTS:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $2.73 -0.29 (-9.60%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Propanc Biopharma Stock (OTCMKTS:PPCB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$2.71▼$3.1050-Day Range$2.73▼$10.4052-Week Range$1.25▼$145.46Volume426,097 shsAverage Volume863,697 shsMarket Capitalization$31.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Read More Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Stock News HeadlinesPropanc Biopharma Announces Plan to Acquire $100 Million of EthereumSeptember 2 at 9:00 AM | globenewswire.comD. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. in Connection with its $4,000,000 UplistingAugust 28, 2025 | finanznachrichten.deEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.September 2 at 2:00 AM | Timothy Sykes (Ad)D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 UplistingAugust 28, 2025 | finance.yahoo.comPropanc Biopharma raises $4 million in Nasdaq debut, plans cancer trialsAugust 26, 2025 | investing.comPropanc Biopharma Provides Shareholder UpdateAugust 25, 2025 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 20, 2025 | finanznachrichten.dePropanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQAugust 19, 2025 | globenewswire.comSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $0.0002 at the start of the year. Since then, PPCB stock has increased by 1,364,900.0% and is now trading at $2.73. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma Inc (OTCMKTS:PPCB) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($12.50) EPS for the quarter. When did Propanc Biopharma's stock split? Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. When does the company's quiet period expire? Propanc Biopharma's quiet period expires on Wednesday, September 24th. Propanc Biopharma had issued 1,000,000 shares in its public offering on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH). Company Calendar Last Earnings5/15/2025Today9/02/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PPCB CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year Founded2007Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-3,652.66% Return on Assets-971.09% Debt Debt-to-Equity Ratio0.01 Current Ratio2.24 Quick Ratio2.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($493.34) per share Price / Book-0.01Miscellaneous Outstanding Shares11,612,000Free Float19,000Market Cap$35.18 million OptionableNot Optionable Beta2.67 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (OTCMKTS:PPCB) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
